← All Zentalis Pharmaceuticals, INC filings

Zentalis Pharmaceuticals, INC 8-K filings

NASDAQ
ZNTL
Zentalis Pharmaceuticals, INC
8-K: Zentalis Pharmaceuticals Announces CFO Resignation and Interim Appointments
Zentalis Pharmaceuticals has announced the resignation of its Chief Financial Officer, Melissa Epperly, and the appointment of interim replacements effective April 5, 2024.
NASDAQ
ZNTL
Zentalis Pharmaceuticals, INC
8-K: Zentalis Pharmaceuticals Highlights Azenosertib's Potential in Oncology Pipeline
Zentalis Pharmaceuticals is advancing its WEE1 inhibitor, azenosertib, with promising clinical data and plans for expansion across multiple cancer types.
NASDAQ
ZNTL
Zentalis Pharmaceuticals, INC
8-K: Zentalis Pharmaceuticals Reports Full Year 2023 Results and Provides Clinical Development Update
Zentalis Pharmaceuticals announced its full year 2023 financial results, highlighted clinical progress with azenosertib, and strengthened its management team.
NASDAQ
ZNTL
Zentalis Pharmaceuticals, INC
8-K: Zentalis Pharmaceuticals Updates Bylaws to Align with SEC Universal Proxy Rules
Zentalis Pharmaceuticals has amended its bylaws to incorporate the SEC's universal proxy rules and streamline procedures for stockholder nominations and proposals.
NASDAQ
ZNTL
Zentalis Pharmaceuticals, INC
8-K: Zentalis Pharmaceuticals Appoints New Chief Medical and Business Officers Amidst Nasdaq Compliance Issue
Zentalis Pharmaceuticals has appointed a new Chief Medical Officer and Chief Business Officer, while also addressing a Nasdaq non-compliance issue related to its Audit Committee composition.